Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zymeworks (ZYME)
:ZYME
Holding ZYME?
Track your performance easily
ZYME Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.97 - $17.70
Previous CloseN/A
Volume35.38K
Average Volume (3M)525.94K
Market Cap
$971.58M
Enterprise Value$678.46M
Total Cash (Recent Filing)$40.26M
Total Debt (Recent Filing)$4.47M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Mar 05, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding68,877,525
10 Day Avg. Volume559,303
30 Day Avg. Volume525,939
Standard Deviation0.15
R-Squared0.14
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)15.55
Price to Cash Flow (P/CF)-41.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue10.91
Enterprise Value/Gross Profit8.93
Enterprise Value/Ebitda-5.77
Forecast
1Y Price Target
$19.93Price Target Upside42.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Zymeworks News
PremiumCompany Announcements
Zymeworks Advances Oncology and Expands Therapeutic Reach
PremiumCompany Announcements
Zymeworks to Showcase Innovations at Investor ConferencesBulls Say, Bears Say
Bulls Say
FDA Approval And MilestonesThe FDA granted accelerated approval to Ziihera (zanidatamab) in pre-treated HER2+ biliary tract cancer patients, validating the company's research and development capabilities and opening doors for further regulatory and commercial milestones, including royalties of 10% to 20% of net sales.
Financial Strength And Development PotentialZymeworks ended 3Q24 with approximately $375 million in cash, providing a financial runway into the second half of 2027, supporting the advancement of its unpartnered pipeline into clinical trials with promising early-stage candidates.
Pipeline Expansion And Investor AttractionThe diverse '5x5' pipeline with different risk profiles is seen as attracting a broad investor base, with the recent announcement of the 5th asset expanding into hematology/oncology and autoimmune and inflammatory diseases.
Bears Say
Clinical TrialsRisks include clinical trial failures due to safety issues and clinical setbacks due to insufficient efficacy.
Pipeline DevelopmentThere is a lack of meaningful clinical catalysts for ZYME's internal pipeline over the next twelve months.
Stock ValuationShares look fully valued at current levels, leading to a downgrade to Equal Weight.
---
Ownership Overview
22.79% Insiders
8.17% Mutual Funds
1.06% Other Institutional Investors
53.39% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZYME FAQ
What was Zymeworks’s price range in the past 12 months?
Zymeworks lowest stock price was $7.97 and its highest was $17.70 in the past 12 months.
What is Zymeworks’s market cap?
Zymeworks’s market cap is $971.58M.
When is Zymeworks’s upcoming earnings report date?
Zymeworks’s upcoming earnings report date is Mar 05, 2025 which is in 46 days.
How were Zymeworks’s earnings last quarter?
Zymeworks released its earnings results on Oct 31, 2024. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.397 by $0.007.
Is Zymeworks overvalued?
According to Wall Street analysts Zymeworks’s price is currently Undervalued.
Does Zymeworks pay dividends?
Zymeworks does not currently pay dividends.
What is Zymeworks’s EPS estimate?
Zymeworks’s EPS estimate is -0.1.
How many shares outstanding does Zymeworks have?
Zymeworks has 68,877,525 shares outstanding.
What happened to Zymeworks’s price movement after its last earnings report?
Zymeworks reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.397. Following the earnings report the stock price went down -3.066%.
Which hedge fund is a major shareholder of Zymeworks?
Among the largest hedge funds holding Zymeworks’s share is Perceptive Advisors LLC. It holds Zymeworks’s shares valued at 27M.
---
Zymeworks Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.93 (42.46% Upside)
$19.93 (42.46% Upside)
Blogger Sentiment
Bullish
ZYME Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 347.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $12.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 10.8%
Last 30 Days ▲ 10.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.73%
12-Months-Change
Fundamentals
Return on Equity
-28.73%
Trailing 12-Months
Asset Growth
-12.44%
Trailing 12-Months
Company Description
Zymeworks
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
---
ZYME Company Deck
---
ZYME Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed sentiment with significant advancements in clinical and preclinical developments, strategic partnerships, and financial management, but also highlighted challenges such as decreased revenue and cash reserves, and a substantial impairment charge.Read More>---
ZYME Stock 12 Month Forecast
Average Price Target
$19.93
▲(42.46% Upside)
Technical Analysis
Immunovant
―
RAPT Therapeutics
―
Immunocore Holdings
―
Mersana Therapeutics
―
Fulcrum Therapeutics
―
Xenon
―
Best Analysts Covering ZYME
1 Year
1 Year Success Rate
13/15 ratings generated profit
1 Year Average Return
+42.47%
assigned a buy rating 3 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +42.47% per trade.
---